Industry
Biotechnology
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Loading...
Open
0.33
Mkt cap
20M
Volume
2.5M
High
0.37
P/E Ratio
-0.13
52-wk high
11.26
Low
0.33
Div yield
N/A
52-wk low
0.26
Portfolio Pulse from richadhand@benzinga.com
June 23, 2023 | 4:01 pm
Portfolio Pulse from Happy Mohamed
June 21, 2023 | 8:04 pm
Portfolio Pulse from richadhand@benzinga.com
June 14, 2023 | 10:18 am
Portfolio Pulse from Charles Gross
May 30, 2023 | 4:06 pm
Portfolio Pulse from Benzinga Insights
May 30, 2023 | 2:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2023 | 12:35 pm
Portfolio Pulse from Happy Mohamed
May 26, 2023 | 12:15 pm
Portfolio Pulse from Charles Gross
May 26, 2023 | 11:56 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.